DANBURY, Conn., July 17, 2007 (PRIME NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) announced today that it has entered into a research, development, commercialization and license agreement with Edison Pharmaceuticals Inc. for the treatment of neurological disorders resulting from defects in cellular energy metabolism.
